الفهرس 
Study of the possible role of cAMP and KATP channels in atorvastatin-induced hepatotoxicity
ContentsOnly 14 pages are availabe for public view
 |  | from | 135 |  |  |
| | | from | 135 | | |
Abstract
Atorvastatin (ATO), a 3-hydroxy-3-methylglutryl-CoA reductase inhibitor, is used widely for treatment of hypercholesterolemia and hypertriglyceridemia. The full clinical utility of ATO has now been somehow limited because of ATO-associated several acute and chronic side effects.The aim of the present work was to investigate the possible mechanism by which cyclic adenosine monophosphate (cAMP) induction or KATP channel opening might affect ATO-induced hepatotoxicity.1- Preliminary study: to determine the most appropriate hepatotoxic regimen (dose and duration) of ATO,depending on measuring alanine transaminase (ALT) and aspartate transaminase (AST) in addition to histopathological liver examination, was performed